Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2023-20

Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2023-2030

Published On : december 2023

Email: help@24marketreports.com

Report Studies The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the RussiaUkraine War were considered while estimating market sizes.

Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.

Email: help@24marketreports.com

Call: +1(646)-781-7170 (Int'l)

By Types Transthyretin Stabilizers

Nonsteroidal Antiinflammatory Drugs (NSAID)

RNAi Therapy

Email: help@24marketreports.com

Call: +1(646)-781-7170 (Int'l)

By Applications • Hereditary Transthyretin Amyloidosis (hATTR) • Wild Type Transthyretin Amyloidosis (wtATTR)

$50,000 $40,000

$35,000 $30,000 $25,000

$30,000 $20,000

$20,000 $15,000 $10,000

$10,000 $0

Email: help@24marketreports.com

Call: +1(646)-781-7170 (Int'l)

$5,000 $0

Get in touch help@24marketreports.com

Call :

Call :

E-mail:

+1(646)-781-7170 (Int'l)

+91 8087042414 (Asia)

URL: www.24marketreports.com

Full Report URL: https://www.24marketreports.com/life-sciences/global-transthyretin-amyloidcardiomyopathy-treatment-forecast-2023-2030-16 ©All Rights Reserved, 24 Market Reports